Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tobramycin + dexamethasone is a fixed-dose combination medication used primarily in ophthalmology. It combines tobramycin, an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria, with dexamethasone, a potent synthetic glucocorticoid corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing the production of inflammatory mediators such as prostaglandins and leukotrienes. This combination is indicated for steroid-responsive inflammatory ocular conditions where there is either an existing superficial bacterial infection or a risk of such infection. The product is available as eye drops and ointment[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tobramycin + dexamethasone.